Literature DB >> 17658892

The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site.

Kari Callaway1, Olga Abramczyk, Lance Martin, Kevin N Dalby.   

Abstract

PEA-15 is a small anti-apoptotic protein that is enriched in astrocytes, but expressed in a broad range of tissues. It sequesters the protein kinases ERK1 and 2 in the cytoplasm, thereby limiting their proximity to nuclear substrates. Using a fluorescence anisotropy approach, PEA-15 is shown to be a high-affinity ligand for both ERK1 and 2, exhibiting a dissociation constant in the range of Kd = 0.2-0.4 microM, regardless of their activation states. Neither the phosphorylation of PEA-15 (phospho Ser-104 and/or phospho Ser-116) nor the phosphorylation of ERK1/2 (by MKK1) significantly affects the stability of the ERK/PEA-15 interaction, and therefore it does not directly regulate the release of ERK2 to the nucleus. The extreme C-terminus of PEA-15 was previously shown by mutagenesis to be important for ERK2 binding; however, the site of binding was not established. Here it is demonstrated that the D-recruitment site (DRS) of ERK2 binds PEA-15, probably at the C-terminus, and renders PEA-15 an inhibitor of ERK2 docking interactions. Using fluorescence anisotropy competition assays it is shown that PEA-15 competes for binding to ERK1/2 with a peptide derived from the D-site of Elk-1, which binds the DRS of ERK1/2. Using modified ERK2 proteins containing single cysteine residues, PEA-15 was shown to protect single cysteines situated within the DRS from alkylation. The pattern and magnitude of protection were very similar to those induced by the binding of the peptide derived from the D-site of Elk-1. These and published data support the notion that PEA-15 binds two sites on ERK1/2 in a bidentate manner: the DRS and a site that includes the MAP kinase insert. Previous reports have suggested that PEA-15 is not an inhibitor of ERK2; however, it is shown here to potently inhibit the ability of ERK2 to phosphorylate two transcription factors, Elk-1 and Ets-1, which contain docking sites for the DRS of ERK2. Therefore, in addition to sequestering ERK1/2 in the cytoplasm, PEA-15 has the potential to modulate the activity of ERK2 in cells by competing directly with proteins that contain D-sites.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17658892     DOI: 10.1021/bi700206u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  Two hydrophobic residues can determine the specificity of mitogen-activated protein kinase docking interactions.

Authors:  A Jane Bardwell; Lee Bardwell
Journal:  J Biol Chem       Date:  2015-09-14       Impact factor: 5.157

2.  Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.

Authors:  Ashraf A Aly; Essmat M El-Sheref; Momtaz E M Bakheet; Mai A E Mourad; Stefan Bräse; Mahmoud A A Ibrahim; Martin Nieger; Boyan K Garvalov; Kevin N Dalby; Tamer S Kaoud
Journal:  Bioorg Chem       Date:  2018-10-23       Impact factor: 5.275

Review 3.  Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases.

Authors:  Michael J Schnieders; Tamer S Kaoud; Chunli Yan; Kevin N Dalby; Pengyu Ren
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity.

Authors:  Kimberly A Burkhard; Fengming Chen; Paul Shapiro
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

5.  Selectivity of docking sites in MAPK kinases.

Authors:  A Jane Bardwell; Erlynn Frankson; Lee Bardwell
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

6.  Local destabilization, rigid body, and fuzzy docking facilitate the phosphorylation of the transcription factor Ets-1 by the mitogen-activated protein kinase ERK2.

Authors:  Andrea Piserchio; Mangalika Warthaka; Tamer S Kaoud; Kari Callaway; Kevin N Dalby; Ranajeet Ghose
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

7.  Phosphorylation of the transcription factor Ets-1 by ERK2: rapid dissociation of ADP and phospho-Ets-1.

Authors:  Kari Callaway; William F Waas; Mark A Rainey; Pengyu Ren; Kevin N Dalby
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

8.  Solution NMR insights into docking interactions involving inactive ERK2.

Authors:  Andrea Piserchio; Mangalika Warthaka; Ashwini K Devkota; Tamer S Kaoud; Sunbae Lee; Olga Abramczyk; Pengyu Ren; Kevin N Dalby; Ranajeet Ghose
Journal:  Biochemistry       Date:  2011-04-19       Impact factor: 3.162

9.  Endogenous, regulatory cysteine sulfenylation of ERK kinases in response to proliferative signals.

Authors:  Jeremiah D Keyes; Derek Parsonage; Rama D Yammani; LeAnn C Rogers; Chelsea Kesty; Cristina M Furdui; Kimberly J Nelson; Leslie B Poole
Journal:  Free Radic Biol Med       Date:  2017-08-24       Impact factor: 7.376

10.  Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) reprograms growth factor signaling by inhibiting threonine phosphorylation of fibroblast receptor substrate 2alpha.

Authors:  Jacob R Haling; Fen Wang; Mark H Ginsberg
Journal:  Mol Biol Cell       Date:  2009-12-23       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.